Navigation Links
Solta Medical Receives Regulatory Approval to Market Thermage Systems in China
Date:4/30/2009

HAYWARD, Calif., April 30 /PRNewswire-FirstCall/ -- Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market, today announced that it has received regulatory clearance to market and sell Thermage(R) systems in China. "We are excited about the opportunity to market the premier non-invasive procedure for tightening and contouring skin in the People's Republic of China," said Stephen J. Fanning, Chairman of the Board, President and CEO of Solta Medical. "We have also applied for regulatory approvals in China for our Fraxel(R) products and expect upon approval that these products will allow us to address additional opportunities in the Chinese market."

About Solta Medical, Inc.

Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective anti-aging solutions for patients which enhance and expand the practice of medical aesthetics for physicians.

The company offers products to address aging skin under the industry's two premier brands: Thermage(R) and Fraxel(R). Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Since 2002, over one million Thermage and Fraxel procedures have been performed in nearly 80 countries. Thermage and Fraxel are the perfect complement for any aesthetic practice. For more information about Solta Medical, call 877-782-2286 or log on to www.Solta.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Solta Medical's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect Solta Medical's business and its financial results are detailed in its Form 10-K for the year ended December 31, 2008, and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. Solta Medical undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

    CONTACT:
    Jack Glenn, Chief Financial Officer of Solta Medical, Inc.,
    +1-510-786-6890; or
    investors,
    Doug Sherk,
    or Jenifer Kirtland, jkirtland@evcgroup.com,
    both of EVC Group, +1-415-896-6820, for Solta Medical, Inc.
    Web Site:http://www.Solta.com


'/>"/>
SOURCE Solta Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Thermage, Inc. Announces Name Change to Solta Medical, Inc.
2. Video: Solta Medical Introduces Advanced Thermage Body Tip 16.0 for Faster Body Shaping and Contouring Treatments
3. Solta Medical, Inc. Announces Preliminary Financial Results for the Fourth Quarter of 2008
4. Solta Medical Reports Fourth Quarter and Full Year 2008 Results
5. Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center
6. Solta Medical, Inc. Secures $9M Credit Facility from Silicon Valley Bank
7. Solta Medical Presents Expert Roundtable about Thermage(R) and Fraxel(R) Combination Treatments at ASLMS Annual Meeting
8. Solta Medical, Inc. Announces First Quarter 2009 Results Release Date and Conference Call
9. MSU engineering team designs innovative medical device
10. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , ... April 29, 2016 , ... ... loans more flexibility in repaying their loans, more information about their loan terms ... when total outstanding student loan debt, including federal and private loans, has reached ...
(Date:4/29/2016)... Petersburg, Fla. (PRWEB) , ... April 29, 2016 ... ... Children’s Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have ... babies is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails ...
(Date:4/29/2016)... Kansas City, Missouri (PRWEB) , ... April 29, 2016 , ... ... Unlike traditional crutches which put pressure on the armpits, the M+D Crutch evenly distributes ... less strain on their wrists and hands when using the crutches than with other ...
(Date:4/29/2016)... ... ... the deadliest type of skin cancer. Although only about 1 percent of skin cancer cases ... 10,000 people are expected to die of melanoma this year. The risk increases with age, ... most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies may give ...
(Date:4/29/2016)... Hills, CA (PRWEB) , ... April 29, 2016 , ... ... of devices and products for the head and neck/ear, nose and throat specialty, has ... Device , The KOTLER NASAL AIRWAY™ is a newly patented safety device ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
(Date:4/28/2016)... 2016 Treato , the ... announced today that it has been named a Cool ... in Life Sciences, 2016, Stephen Davies , ... focuses on life-science- oriented analytics, algorithms and smart machine ... doctors, confirm medication ingestion, and analyze unstructured information.   ...
(Date:4/28/2016)... 2016  ValGenesis, Inc., the market leader ... today announced that a prominent world provider ... chronic kidney failure has selected ValGenesis Validation ... validation process. The global medical device manufacturer ... manage their validation processes electronically. Upon completion ...
Breaking Medicine Technology: